Literature DB >> 14976230

2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.

John J McGuire1, Mahmoud Saifeddine, Chris R Triggle, Kimberly Sun, Morley D Hollenberg.   

Abstract

A peptide corresponding to a proteinase-activated receptor 2 (PAR(2))-activating peptide with an N-terminal furoyl group modification, 2-furoyl-LIGRLO-NH(2), was assessed for PAR(2)-dependent and -independent biological activities. 2-Furoyl-LIGRLO-NH(2) was equally effective to and 10 to 25 times more potent than SLIGRLNH(2) for increasing intracellular calcium in cultured human and rat PAR(2)-expressing cells, respectively. In bioassays of tissue PAR(2) activity, measured as arterial vasodilation and hyperpolarization, 2-furoyl-LIGRLO-NH(2) was 10 to 300 times more potent than SLIGRL-NH(2). Unlike trans-cinnamoyl-LIGRLO-NH(2), 2-furoyl-LI-GRLO-NH(2) did not cause a prominent non-PAR(2)-mediated contraction of murine femoral arteries. In conclusion, 2-furoyl-LI-GRLO-NH(2) represents the most potent and selective activator of PAR(2) in biological systems described to date.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976230     DOI: 10.1124/jpet.103.064584

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

1.  Activation of protease activated receptor 2 by exogenous agonist exacerbates early radiation injury in rat intestine.

Authors:  Junru Wang; Marjan Boerma; Ashwini Kulkarni; Morley D Hollenberg; Martin Hauer-Jensen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-15       Impact factor: 7.038

2.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

Review 3.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

4.  Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation.

Authors:  Xiaorong Xu Parks; Elsa Ronzier; Jin O-Uchi; Coeli M Lopes
Journal:  J Mol Cell Cardiol       Date:  2019-03-18       Impact factor: 5.000

5.  Proteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways.

Authors:  Mahmoud El-Daly; Mahmoud Saifeddine; Koichiro Mihara; Rithwik Ramachandran; Christopher R Triggle; Morley D Hollenberg
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  PAR2 Mediates Itch via TRPV3 Signaling in Keratinocytes.

Authors:  Jiahui Zhao; Admire Munanairi; Xian-Yu Liu; Jie Zhang; Linghan Hu; Meiqin Hu; Dingfang Bu; Lingling Liu; Zhiqiang Xie; Brian S Kim; Yong Yang; Zhou-Feng Chen
Journal:  J Invest Dermatol       Date:  2020-01-29       Impact factor: 8.551

Review 8.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

9.  Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells.

Authors:  Jacky Y Suen; Brooke Gardiner; Sean Grimmond; David P Fairlie
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

10.  Beta-arrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2.

Authors:  Ping Wang; Yong Jiang; Yinsheng Wang; John Y Shyy; Kathryn A DeFea
Journal:  BMC Biochem       Date:  2010-09-21       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.